ArticleJournal of cancer research and clinical oncology2022
Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 6 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pooled it
- Non-targeted effects of stereotactic radiotherapy: a review of the evidence coming from the clinical field.Exploration of targeted anti-tumor therapy · 2025Pooled it
- The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.Journal of neuro-oncology · 2023Pooled it
- Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis.Cancer research and treatment · 2022Pooled it
- Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study.Cancer pathogenesis and therapy · 2025Article
- Research progress on treatment-associated pneumonitis in lung cancer patients undergoing radiotherapy and immunotherapy.Future oncology (London, England) · 2025Review
- Safety and toxicity risks of radiotherapy combined with PD-1/PD-L1 inhibitors: A comprehensive review.iScience · 2025Review
- Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study.Cancer immunology, immunotherapy : CII · 2025Observational
- Combining immune checkpoint inhibitors with thoracic radiotherapy enhances outcomes in advanced non-small-cell lung cancer: a real-world study.Frontiers in oncology · 2025Article
- Immune checkpoint inhibitors with or without radiotherapy in metastatic non‑small cell lung cancer: A meta‑analysis and literature review.Oncology letters · 2024Article
- Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy.Cancer immunology, immunotherapy : CII · 2024Article
- Oligometastasis: Expansion of Curative Treatments in the Field of Oncology.Medicina (Kaunas, Lithuania) · 2023Review
- Efficacy and safety of immunoradiotherapy for advanced non-small cell lung cancer: a retrospective comparative cohort study.Journal of thoracic disease · 2023Article
- Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.Translational lung cancer research · 2023Review
- Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy.Cancer management and research · 2023Article
- Article
- Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis.Frontiers in immunology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
purposeGrowing numbers of clinical trials test the efficacy of radiotherapy (RT) plus immune checkpoint inhibitors (ICIs), but the number of irradiated sites is not uniform. We aimed to evaluate the efficacy of single-site RT plus immunotherapy in oligometastatic non-small cell lung cancer (NSCLC) with smaller disease burdens and low tumor heterogeneity.
methodsWe retrospectively identified oligometastatic NSCLC (< 4 metastatic sites) patients treated with PD-1 pathway inhibitors with or without RT to a single lesion in our institution between 2018 and 2020. The primary endpoints were the best objective response rate (ORR) and progression-free survival (PFS).
resultsOf the 152 patients enrolled, 93 and 59 were identified as the ICI alone group and the ICI plus RT group, respectively. The addition of RT to ICI therapy significantly increased the best ORR from 31.2% to 50.8% (p = 0.015). The out-of-field (abscopal effect) response rate could reach 41.3% (95%CI 26.5%-56.1%) in the ICI plus RT group. Median PFS was 8.9 months (95%CI 4.7-13.1 months) with ICI alone versus 13.8 months (95%CI 9.5-18.1 months) with ICI plus radiotherapy (hazard ratio [HR] 0.556; p = 0.035). In an exploratory subgroup analysis of PFS, the addition of RT brought greater benefits in patients aged < 65 years (p = 0.016), patients with ECOG PS = 0 (p = 0.048), and patients with 1-2 metastatic sites (p = 0.024). No unexpected adverse events or significantly increased toxicities were observed in the experimental arm.
conclusionSingle-site RT plus anti-PD-1 inhibitors significantly increased systemic responses and improved survival outcomes in oligometastatic NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.